Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2025-04-09 | 2025-04-08 |
| Drug Identification Number | 02248302 | 02248302 |
| Brand name | MULTIHANCE | MULTIHANCE |
| Common or Proper name | Gadobenate Dimeglumine injection | Gadobenate Dimeglumine injection |
| Company Name | BRACCO IMAGING CANADA | BRACCO IMAGING CANADA |
| Ingredients | GADOBENATE DIMEGLUMINE | GADOBENATE DIMEGLUMINE |
| Strength(s) | 529MG | 529MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | Box of 5 vials of 50ml | Box of 5 vials of 50ml |
| ATC code | V08CA | V08CA |
| ATC description | MAGNETIC RESONANCE IMAGING CONTRAST MEDIA | MAGNETIC RESONANCE IMAGING CONTRAST MEDIA |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2025-05-31 | 2025-05-31 |
| Actual start date | ||
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | The anticipated shortage is related to delays in manufacturing planning. Bracco would like to reassure its customers that the shortage is unrelated to to tariffs or retaliatory trade measures | Delays in the manufacturing planning |
| Health Canada comments |